posted on 2009-05-14, 00:00authored byEric E. Boros, Cynthia E. Edwards, Scott A. Foster, Masahiro Fuji, Tamio Fujiwara, Edward P. Garvey, Pamela L. Golden, Richard J. Hazen, Jerry L. Jeffrey, Brian A. Johns, Takashi Kawasuji, Ryuichi Kiyama, Cecilia S. Koble, Noriyuki Kurose, Wayne H. Miller, Angela L. Mote, Hitoshi Murai, Akihiko Sato, James B. Thompson, Mark C. Woodward, Tomokazu Yoshinaga
The medicinal chemistry and structure−activity relationships for a novel series of 7-benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV-integrase inhibitors are disclosed. Substituent effects were evaluated at the N-1, C-3, and 7-benzyl positions of the naphthyridinone ring system. Low nanomolar IC50 values were achieved in an HIV-integrase strand transfer assay with both carboxylic ester and carboxamide groups at C-3. More importantly, several carboxamide congeners showed potent antiviral activity in cellular assays. A 7-benzyl substituent was found to be critical for potent enzyme inhibition, and an N-(2-methoxyethyl)carboxamide moiety at C-3 significantly reduced plasma protein binding effects in vitro. Pharmacokinetic data in rats for one carboxamide analogue demonstrated oral bioavailability and reasonable in vivo clearance.